Novartis: FDA approves rare genetic disorder treatment
(CercleFinance.com) - Novartis said on Tuesday that the US Food and Drug Administration has approved Afinitor Disperz for the treatment of seizures associated with tuberous sclerosis complex, a rare genetic disorder affecting up to one million people worldwide.
The decision makes the drug the first approved pharmacologic therapy in the US that is specifically indicated for the treatment of this condition, the Swiss drugmaker said.
Approximately 85% of people with tuberous sclerosis complex are affected by epilepsy, and uncontrolled seizures, Novartis said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The decision makes the drug the first approved pharmacologic therapy in the US that is specifically indicated for the treatment of this condition, the Swiss drugmaker said.
Approximately 85% of people with tuberous sclerosis complex are affected by epilepsy, and uncontrolled seizures, Novartis said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.